Section Arrow
ORKA.NASDAQ
- Oruka Therapeutics Inc
Quotes are at least 15-min delayed:2025/07/07 00:48 EDT
Last
 12.6
-0.01 (-0.08%)
Day High 
12.925 
Prev. Close
12.61 
1-M High
13.7 
Volume 
148.95K 
Bid
8
Ask
13.7
Day Low
12.1 
Open
12.74 
1-M Low
10.77 
Market Cap 
472.12M 
Currency USD 
P/E -- 
%Yield 67.21 
10-SMA 11.63 
20-SMA 12.04 
50-SMA 11.09 
52-W High 52.32 
52-W Low 5.485 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.88/-2.76
Enterprise Value
472.88M
Balance Sheet
Book Value Per Share
26.94
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
WINTWindtree Therapeutics Inc.0.9292+0.1592+20.68%0.84PE
LIXTLixte Biotechnology Holdings2.83+0.81+40.10%-- 
NCNANuCana plc0.0536-0.0029-5.13%-- 
CMNDClearmind Medicine1.1+0.197+21.82%0.16PE
VORVor Biopharma1.91+0.46+31.72%-- 
Quotes are at least 15-min delayed:2025/07/07 00:48 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.